<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145219</url>
  </required_header>
  <id_info>
    <org_study_id>MT-12</org_study_id>
    <nct_id>NCT04145219</nct_id>
  </id_info>
  <brief_title>Mite Allergy Trial In Children</brief_title>
  <acronym>MATIC</acronym>
  <official_title>A One-year Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) SLIT-tablet in Children (5-11 Years of Age) With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study of how house dust mite tablets work compared to placebo in children aged
      between 5 and 11 years and who have allergy to house dust mites (MATIC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet compared to placebo
      in children (5-11 years of age) with House Dust Mite allergic rhinitis based on the total
      combined rhinitis symptoms and medication score during the last 8 weeks of treatment.

      In addition, the trial will evaluate safety and tolerability of the treatment, and assess
      whether treatment has an impact on asthma symptoms and medication use, immunological
      parameters, and rhinoconjunctivitis quality of life (QoL).

      The trial is a randomised, parallel-group, double-blind, placebo-controlled multi-national
      phase III trial conducted in Europe and North America. The treatment period will be
      approximately 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Combined rhinitis symptoms and medication use</measure>
    <time_frame>The last 8 weeks of approximately 12 months of treatment</time_frame>
    <description>The average daily sum of a rhinitis symptoms score and rhinitis medication score measured on a common scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rhinitis symptoms</measure>
    <time_frame>The last 8 weeks of approximately 12 months of treatment</time_frame>
    <description>The average of a daily rhinitis symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinitis medication</measure>
    <time_frame>The last 8 weeks of approximately 12 months of treatment</time_frame>
    <description>The average of a daily rhinitis medication score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined rhinoconjunctivitis symptoms and medication use</measure>
    <time_frame>The last 8 weeks of approximately 12 months of treatment</time_frame>
    <description>The average daily sum of a rhinoconjunctivitis symptoms score and rhinoconjunctivitis medication score measured on a common scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>From first subject screened until last subject last visit</time_frame>
    <description>Adverse events and assessment of lung function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1370</enrollment>
  <condition>Allergic Rhinitis Due to Dermatophagoides Farinae</condition>
  <condition>Allergic Rhinitis Due to Dermatophagoides Pteronyssinus</condition>
  <condition>Allergic Rhinitis Due to House Dust Mite</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDM SLIT-tablet plus allergy and asthma rescue medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablet plus allergy and asthma rescue medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sublingual allergy immunotherapy tablet</intervention_name>
    <description>For daily administration (1 tablet per day)</description>
    <arm_group_label>Active treatment</arm_group_label>
    <other_name>Acarizax</other_name>
    <other_name>Odactra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For daily administration (1 tablet per day)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo sublingual tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 5-11 years

          -  A clinical history of HDM AR/C (with or without asthma) and with allergic rhinitis
             symptoms despite having received allergy pharmacotherapy during the previous year
             prior to screening

          -  Have a certain level of AR symptoms on at least 8 of the last 14 days of the baseline
             period

          -  Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of
             the last 14 days of the baseline period

          -  Positive skin prick test (SPT) and IgE to D. pteronyssinus or D. farinae at screening

          -  Lung function ≥ 70% of predicted value

        Exclusion Criteria:

          -  Sensitised and regularly exposed to perennial allergens

          -  Any nasal or pharyngeal condition that could interfere with the safety or efficacy
             evaluation

          -  Asthma requiring treatment with high dose of inhaled corticosteroid

          -  A relevant history of systemic allergic reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antje Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Pediatrics, Düsseldorf University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorthe Thrane, MSc</last_name>
    <phone>+45 45747576</phone>
    <email>clinicaltrials@alk.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Rud Pedersen, MSc</last_name>
    <phone>+45 45747576</phone>
    <email>clinicaltrials@alk.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>California Allergy and Asthma Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski Malgorzata Pawlukiewicz</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawlukiewicz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Сity Children's Polyclinic No 35</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rivas, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic rhinitis</keyword>
  <keyword>HDM</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

